Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

News
Patient-Reported Outcomes Show Comparable Quality of Life in Pembrolizumab Plus CCRT for High-Risk, Locally Advanced Cervical Cancer
03/20/2024

Brandon Twyford

Brandon Twyford
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the...
03/20/2024
Journal of Clinical Pathways
John Allan, MD
Conference Coverage
Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape
03/20/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia &...
03/20/2024
Lymphoma, Leukemia & Myeloma Network
News
ChatGPT Vs Multidisciplinary Tumor Board: Treatment Recommendations for Patients With Gynecologic Cancers
03/19/2024

Grace Taylor

Grace Taylor
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and...
03/19/2024
Journal of Clinical Pathways

Advertisement

News
Cost-Effectiveness Analysis of Immunotherapy Regimes in Upfront Treatment With Chemotherapy for Endometrial Cancer
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways

Advertisement

News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
Brian M. Slomovitz, MD
Conference Coverage
Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways

Advertisement

Conference Coverage
Addition of Induction Chemotherapy to Chemoradiation Improves Survival Outcomes Among Patients with Locally Advanced Cervical Cancer
03/17/2024

Allison Casey

Allison Casey
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial,...
03/17/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use